When the Global Fund terminated its grants to the Democratic People’s Republic of Korea (DPRK), also known as North Korea, on 21 February 2018, the Fund said, “We remain committed to supporting the health of the people in DPRK, and hope to re-engage when possible.”
You are here
On 22 March 2019, the Global Fund Board approved funding for two country grants and supplementary funding for a third –– for a total value of $11.0 million. Interventions worth $4.1 million were added to the Unfunded Quality Demand (UQD) Register. Domestic commitments for the programs included in the approved country grants amounted to $28.5 million. (See Table 1 for details.)
On 31 January 2019, the Global Fund Board approved three country grants worth $13.4 million. It also approved two multicountry grants valued at $22.5 million. The Board was acting on the recommendations of the Technical Review Panel (TRP) and the Grant Approvals Committee (GAC). See Tables 1 and 2 for listings of the country and multi-country grants.
Of the $98 million in country grants approved by Global Fund Board from 2017-2019 allocations, Latin America and Caribbean receive $57 million
This is the second of two articles in this issue on the grants recently approved by the Global Fund Board. In this article, we report on the comments of the Grant Approvals Committee (GAC) on four countries in the Latin American and Caribbean region: Belize, El Salvador, Panama and Paraguay.
On 12 November 2018, through electronic voting, the Global Fund Board approved $98.0 million in funding for 14 country grants from 13 countries. Of the 14 grants, four were for TB; three TB/HIV; three HIV; three malaria; and one TB/RSSH.
On 17 August 2018 and on 26 October 2018, the Global Fund Board approved two HIV grants and three TB grants worth $28.1 million. The Board also approved $15.9 million in matching funds requests for six components.